Elucidating arrhythmogenic right ventricular cardiomyopathy with stem cells

Birth Defects Res. 2022 Oct 1;114(16):948-958. doi: 10.1002/bdr2.2010. Epub 2022 Apr 9.

Abstract

Human stems cells have sparked many novel strategies for treating heart disease and for elucidating their underlying mechanisms. For example, arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited heart muscle disorder that is associated with fatal arrhythmias often occurring in healthy young adults. Fibro-fatty infiltrate, a clinical hallmark, progresses with the disease and can develop across both ventricles. Pathogenic variants in genes have been identified, with most being responsible for encoding cardiac desmosome proteins that reside at myocyte boundaries that are critical for cell-to-cell coupling. Despite some understanding of the molecular signaling mechanisms associated with ARVC mutations, their relationship with arrhythmogenesis is complex and not well understood for a monogenetic disorder. This review article focuses on arrhythmia mechanisms in ARVC based on clinical and animal studies and their relationship with disease causing variants. We also discuss the ways in which stem cells can be leveraged to improve our understanding of the role cardiac myocytes, nonmyocytes, metabolic signals, and inflammatory mediators play in an early onset disease such as ARVC.

Keywords: ARVC; arrhythmia; cardiomyopathy; cytokines; desmosomes; gene mutations; stem cells.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arrhythmogenic Right Ventricular Dysplasia* / genetics
  • Arrhythmogenic Right Ventricular Dysplasia* / pathology
  • Heart Ventricles
  • Humans
  • Mutation
  • Stem Cells